Declan Flynn
Pfizer (United States)(US)
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Adipose Tissue and Metabolism, Nitric Oxide and Endothelin Effects, Computational Drug Discovery Methods, Peroxisome Proliferator-Activated Receptors
Most-Cited Works
- → SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1(2010)890 cited
- → Activation of Skeletal Muscle AMPK Promotes Glucose Disposal and Glucose Lowering in Non-human Primates and Mice(2017)260 cited
- → Efficacy of telemedicine on glycaemic control in patients with type 2 diabetes: A meta-analysis(2021)75 cited
- → Discovery of a Series of Imidazo[4,5-b]pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-γ(2011)52 cited
- → Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists(2012)47 cited
- → Optimization of triazole-based TGR5 agonists towards orally available agents(2012)31 cited
- → Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ(2012)26 cited
- → Behavioral effects and receptor binding affinities of fentanyl derivatives in rhesus monkeys.(1995)25 cited
- → Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™(2022)17 cited
- → Statistical power analysis of cardiovascular safety pharmacology studies in conscious rats(2016)12 cited